Insider: Nayak Sanjay Chief Strategy Officer - OCULAR THERAPEUTIX, INC
| Company Holdings |
| Direct | Indirect Ownership | Total | |
| Shares | 279,738 | 0 | 279,738 |
| Value | $3,505,117.14 | $0.00 | $3,505,117.14 |
Trans. Date |
Trans. Type |
Shares |
Ownership Type |
Issue Type |
Price |
Trans. Value |
Total Shares Owned |
|---|---|---|---|---|---|---|---|
| 08/25/2025 | DDS | 1,885 | Direct | COM | $12.04 | $22,695.40 | 279,738 |
| 05/23/2025 | DDS | 1,862 | Direct | COM | $7.17 | $13,350.54 | 281,623 |
| 02/24/2025 | DDS | 1,895 | Direct | COM | $6.84 | $12,961.80 | 283,485 |
| 11/25/2024 | DDS | 1,814 | Direct | COM | $9.00 | $16,326.00 | 174,380 |
| 08/23/2024 | DDS | 1,832 | Direct | COM | $9.02 | $16,524.64 | 176,194 |
| 05/23/2024 | DDS | 2,274 | Direct | COM | $5.84 | $13,280.16 | 178,026 |
| 1 You are at page 1 of 1 pages |
|
Transaction Type Key First letter: A = Acquired, D = Disposed Second letter: A = Grant, award or other acquisition pursuant to Rule 16b-3(d) C = Conversion of derivative security | D = Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | E = Expiration of short derivative position | F = Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. | G = Gift | H = Expiration (or cancellation) of long derivative position with value received | I = Discretionary transaction in accordance with Rule 16b-3(f) | J = Other | L = Small acquisition under Rule 16a-6 | M = Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | O = Exercise of out-of-the-money derivative security | P = Open market or private purchase | S = Open market or private sale | U = Disposition pursuant to a tender of shares in a change of control transaction | W = Acquisition or disposition by will or the laws of descent and distribution | X = Exercise of in-the-money or at-the-money derivative security | Z = Deposit into or withdrawal from voting trust |
 |
Send to Excel |
© 2000 - 2025 Zacks Investment Research